EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds
Portfolio Pulse from Vandana Singh
Clearmind Medicine Inc (NASDAQ:CMND) and SciSparc Ltd (NASDAQ:SPRC) have submitted three new international patent applications for MDMA, Ibogaine, and Ketamine compounds in collaboration. These applications aim to expand their intellectual property in the psychedelic space, with Clearmind now holding 27 granted patents and 24 pending applications. Additionally, Clearmind received approval to commence a phase 1/2a trial in Israel for alcohol use disorder using its CMND-100 oral capsule. CMND shares dropped 1.73% in premarket trading.
February 27, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Clearmind Medicine Inc has submitted three new international patent applications in collaboration with SciSparc, aiming to expand its IP in the psychedelic space. The company also received approval for a phase 1/2a trial in Israel for alcohol use disorder.
The submission of new patent applications and the commencement of a clinical trial represent significant positive developments for Clearmind, likely to enhance its IP portfolio and clinical progress. However, the short-term stock price dip suggests market reactions may vary.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
SciSparc Ltd collaborates with Clearmind Medicine Inc on submitting three new international patent applications for psychedelic compounds, aiming to strengthen their position in the psychedelic space.
The collaboration with Clearmind for the submission of patent applications could enhance SciSparc's visibility and credibility in the psychedelic and biotech sectors. This strategic move is likely to have a positive impact on SciSparc's market position.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 70